The Biology Police: The Plavix Investigation and Pharmacogenomics
This article was originally published in RPM Report
The discovery of a genetic marker for Plavix resistance is one of the milestones in the regulatory application of pharmacogenomics. Is it also a crime drama?
You may also be interested in...
AstraZeneca, Merck, Novartis and Sanofi are also under investigation for potential health care fraud.
HHS Office of Inspector General’s Mary Riordan advises drug makers to analyze their speaker programs and consulting arrangements for possible kickback activities.
An Institute of Medicine workshop on companion diagnostics suggests that regulatory standards are evolving at FDA to encourage companion diagnostic development. But almost everything else is still a challenge.